Lupin Q1 FY27 Results: Sales Surge 33% YoY to ₹82,172 Mn, EBITDA Grows 50% YoY
Lupin Limited reported Q1 FY27 results with sales at ₹82,172 million, up 33% YoY. EBITDA increased 50% YoY to ₹24,635 million, with margins at 30.0%. Net income grew 16% YoY to ₹14,150 million. Key markets India and North America showed strong performance.
The significant year-on-year growth in key financial metrics like sales and EBITDA, coupled with positive regulatory news and product launches, is expected to have a substantial positive impact on the company's stock.
The company reported strong year-on-year growth in sales, EBITDA, and net income, along with improved margins and positive developments in product launches and regulatory approvals.
Lupin Limited announced its unaudited financial results for the quarter ended June 30, 2026, reporting a significant increase in performance. The company's sales reached ₹82,172 million, a 33% year-on-year increase, driven by strong growth across its key markets. North America contributed ₹35,908 million, up 43% YoY, while India sales were ₹23,796 million, a 14% YoY increase.
EBITDA saw a substantial 50% YoY jump to ₹24,635 million, with the EBITDA margin improving to 30.0% from 26.6% in the prior year's comparable quarter. Net income for the quarter stood at ₹14,150 million, marking a 16% YoY growth. The company highlighted key developments including regulatory approvals for its Nagpur Unit I & II from HLfGP (Germany) and CDSCO approval for Ankleshwar.
In terms of business development, Lupin received EMA approval to extend NaMuscla® for children and secured China approval for Oseltamivir Phosphate oral suspension. The company also launched Luforbec® in Spain and presented positive Phase 1a data for its novel SOS1 inhibitor LNP8701 at ASCO 2026. The US FDA approved Azilsartan Medoxomil Tabs and Ranibizumab biosimilar.
Lupin's strategic focus remains on outperforming market growth, particularly in India where its Rx business grew 15.1% YoY, exceeding the IPM growth. The company is also expanding its digital offerings and diagnostics platform. In the United States, growth was driven by volume increases in the base business, despite increased competition. Lupin is investing in complex generics and biosimilars, with plans to file over 15 ANDAs and launch 5+ biosimilars by FY31. The company also emphasized its commitment to quality and regulatory compliance, with successful inspections across multiple sites.
What to do with a filing like this
Lupin Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lupin Limited. Read the original for the full detail.